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Abstract
Background: Prostate cancer progression to androgen independence is the primary cause of
mortality by this tumor type. The IGF-1/IGF-1R axis is well known to contribute to prostate cancer
initiation, but its contribution to invasiveness and the downstream signalling mechanisms that are
involved are unclear at present.
Results: We examined the invasive response of androgen independent DU145 prostate carcinoma
cells to IGF-1 stimulation using Matrigel assays. We then examined the signaling mechanisms and
protease activities that are associated with this response. IGF-1 significantly increased the invasive
capacity of DU145 cells in vitro, and this increase was inhibited by blocking IGF-1R. We further
demonstrated that specific inhibitors of the MAPK and PI3-K pathways decrease IGF-1-mediated
invasion. To determine potential molecular mechanisms for this change in invasive capacity, we
examined changes in expression and activity of matrix metalloproteinases. We observed that IGF-
1 increases the enzymatic activity of MMP-2 and MMP-9 in DU145 cells. These changes in activity
are due to differences in expression in the case of MMP-9 but not in the case of MMP-2. This
observation is corroborated by the fact that correlated changes of expression in a regulator of
MMP-2, TIMP-2, were also seen.
Conclusion: This work identifies a specific effect of IGF-1 on the invasive capacity of DU145
prostate cancer cells, and furthermore delineates mechanisms that contribute to this effect.
Background
Insulin-like growth factor 1 (IGF-1), via binding to the
IGF-1 receptor (IGF-1R), is thought to contribute to the
development of prostate cancer by promoting prolifera-
tion and blocking apoptosis [1,2], which likely account
for the epidemiological findings of association between
IGF-1 or elements of its regulatory system and the devel-
opment of prostate cancer [3]. The role of IGF-1 in the
progression of prostate cancer to an invasive and meta-
static phenotype is still unclear, although it has been stud-
ied in other tumour types. Increased IGF-1R signalling is
associated with an upregulation of extracellular proteases
necessary for tumour cell invasion in lung and breast can-
cer [4], and suppression of IGF-1R in breast cancer
decreases tumour metastasis in vivo [5]. The association
between IGF-1R and prostate cancer progression is less
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clear. There is clinical data showing lack of correlation
between IGF-1 levels and stage of disease [6,7], yet there is
also evidence of significantly increased IGF-1R expression
in advanced disease [8]. Furthermore, data from an ani-
mal model of prostate cancer progression and a prostate
cancer cell line indicate an effect of IGF-1R signalling on
invasion [9,10]. This suggestive data, however, does not
establish a direct causative role for IGF-1 signalling in the
promotion of prostate cancer progression to an invasive
phenotype. IGF-1/IGF-1R activates a number of signalling
pathways, including the phosphatidylinositol-3 kinase
(PI3-K) pathway, the protein kinase C pathway, the CREB
pathway and the mitogen activated protein kinase
(MAPK) pathway [11-14], but the relative contribution of
these pathways in prostate cancer cell invasion is
unknown. Prostate cancer often exhibits inactivation of a
major regulator of the PI3-K pathway, PTEN, leading to
deregulation and constitutive activation of this pathway.
Thus, the contribution of these two pathways to IGF-1-
stimulated invasion of prostate cells requires further anal-
ysis. In order to do this, we studied IGF-1-stimulated inva-
sion in the DU145 cell line, which is the only
commercially available prostate cancer cell line without
PTEN inactivating mutations and an intact, tightly regu-
lated PI-3 kinase pathway[15-17]. Our study specifically
determined that IGF-1/IGF-1R signaling via the PI3-K and
MAPK pathways augments the invasive phenotype of
these prostate cancer cells, and that this regulation is at
least partially attributed to an increase in the activity, but
not necessarily in the expression, of MMP-2 and MMP-9.
Methods
Cell culture and Matrigel invasion assay
The DU145 cell line, obtained from the American Type
Culture Collection (Manassas, VA), was cultured in Dul-
becco's modified eagle's medium (DMEM; Sigma-Aldrich
Canada Ltd., Oakville, ON) supplemented with 10% fetal
bovine serum (FBS; HyClone, Logan, UT), 50 μg/ml pen-
icillin G sodium and 50 μg/ml streptomycin sulfate (Inv-
itrogen Canada Inc., Burlington, ON). IGF-1 was obtained
lyophilized from Sigma-Aldrich and reconstituted in dis-
tilled water. Fifty thousand DU145 cells were added per
invasion chamber coated with Matrigel (reconstituted
basement membrane; BD Biosciences, Mississauga, ON).
Cells were allowed to invade for 24 hours towards media
containing 10% FBS and the number of invaded cells were
counted according to the manufacturer's instructions.
Where indicated, one of three inhibitors were used: 100
nM wortmannin (Sigma-Aldrich), a concentration chosen
from a range used in the literature[18-20]; 50 μM
PD98059 (Sigma-Aldrich), a concentration chosen from a
range used in the literature[18,21,22]; or 1 μg/mL of an
IGF-1R neutralizing antibody, MAB391 (R&D Systems,
Inc., Minneapolis, MN), a concentration equivalent to
about 6 nM, found to be effective in significantly reducing
IGF-1R phosphorylation[23].
Preparation of cell lysates and conditioned media
Washed cell pellets were lysed in 1% NP-40, 150 mM
NaCl, 50 mM Tris pH7.6, 1 mM EDTA containing 10%
protease inhibitor cocktail (Roche Diagnostics, Laval,
QC) and kept on ice for 1 hour with intermittent vortex-
ing. Extracts were centrifuged at 1000 rpm for 5 minutes
at 4°C and the supernatant was collected. Protein levels
were quantified using the Bradford assay (Bio-Rad Labo-
ratories, Mississauga, ON). Conditioned media was cen-
trifuged at 1000 rpm for 5 minutes at 4°C to eliminate
cellular debris. Cell number was determined for each sam-
ple. The media was concentrated using Amicon Ultra-4
centrifugal filter units (Millipore Canada, Etobicoke, ON)
with a molecular weight cut-off of 10 kD, as per the man-
ufacturer's recommendations.
Immunoblot analysis
Proteins were separated by SDS-PAGE and transferred to a
PVDF membrane (Bio-Rad). Membranes were probed
with the relevant primary antibodies: mouse anti-MMP-2
monoclonal Ab (1:100, Oncogene Research Products, La
Jolla, CA); mouse anti-MMP-9 monoclonal Ab (1:200,
R&D Systems); goat anti-MMP-9 polyclonal Ab (1:1000,
Santa Cruz Biotechnology, Inc., Santa Cruz, CA); mouse
anti-P-Akt monoclonal Ab (1:1000, Cell Signaling Tech-
nology, Inc., Danvers, MA); rabbit anti-P-MAPK polyclo-
nal Ab (1:1000, Cell Signaling); mouse anti-TIMP-1
monoclonal Ab (1:100, Cedarlane Laboratories, Hornby,
ON); mouse anti-TIMP-2 monoclonal Ab (1:400, Cedar-
lane Laboratories) and mouse anti-actin monoclonal Ab
(1:10 000, MP Biomedicals, Inc., Aurora, OH). Secondary
antibodies were all horseradish peroxidase conjugated
[goat anti-mouse IgG (Bio-Rad); goat anti-rabbit IgG (Bio-
Rad); donkey anti-goat IgG (Bio-Rad), all at 1:10000]. Vis-
ualization of antibody binding was carried out using
enhanced chemiluminescence (ECL; Perkin Elmer Life
Sciences, Woodbridge, ON) and exposure to Kodak X-
OMAT film.
Gelatin zymography
Conditioned media was prepared in sample buffer (0.25
M Tris-HCl pH6.8, 10% SDS, 4% sucrose, 0.1%
bromophenol blue) and electrophoresed on 8% polyacr-
ylamide gels containing 0.3% gelatin. The gels were
washed with 2.5% Triton X in dH2O and incubated for 48
hours at 37°C in substrate buffer (50 mM Tris-HCl, 0.2 M
NaCl, 5 mM CaCl2, 0.02% Brij35). After incubation, the
gels were stained with Coomassie Blue solution (10% gla-
cial acetic acid, 30% isopropanol, 0.5% Coomassie Blue
R250), destained (40% methanol, 10% acetic acid, 50%
water) until clear bands representing zymogen activity
appeared, then dried.Cancer Cell International 2008, 8:10 http://www.cancerci.com/content/8/1/10
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Results
IGF-1 increases the invasive potential of DU145 prostate 
cancer cells through the IGF-1R, via both the PI3-K and 
MAPK pathways
The effect of IGF-1 on the in vitro invasive potential of
DU145 cells was investigated using Matrigel invasion
assays. Figure 1A shows that IGF-1 treatment results in a
dose-responsive increase in the invasive potential of
DU145 cells compared to untreated cells. When DU145
cells were treated with an IGF-1R neutralizing antibody
that competes with IGF-1 binding to IGF-1R and induces
receptor degradation [23], the IGF-1-induced increase in
invasion of DU145 cells was attenuated to close to base-
line values (Fig. 1B). This indicates that the observed inva-
sive phenotype of DU145 cells is due specifically to IGF-1
signalling through its receptor. To study the effects of IGF-
1 via the PI3-K pathway, P-Akt levels were assessed and
found to be upregulated in DU145 cells following 1-hour
IGF-1 treatment (Fig. 1C). This stimulation is inhibited by
wortmannin, a selective, irreversible inhibitor of the PI3-
K pathway, but not by PD98059, a potent inhibitor of the
MAPK pathway. We next evaluated the activation of the
MAPK pathway by IGF-1 by determining increases in
phosphorylated p42/44 MAPK (p42/44 P-MAPK). We
noted an increase in p42/44 P-MAPK with IGF-1 stimula-
tion that decreased to baseline levels in the presence of
PD98059 but not wortmannin (Fig. 1D). The increased
invasion of DU145 cells induced by IGF-1 was signifi-
cantly inhibited in the presence of either wortmannin (by
a ratio of 0.79 +/- 0.083) or PD98059 (by a ratio of 0.37
+/- 0.096) (Fig. 1E&1F). This data indicates a regulatory
role of IGF-1 signalling in invasion via both the PI3-K and
MAPK pathways.
IGF-1 regulates MMP-2 and MMP-9 activity and 
expression via the PI3-K and MAPK pathways
MMPs have been identified as being highly associated
with prostate cancer invasion [24]. Gelatin zymography,
analyzing the ability of MMPs to degrade gelatin, was per-
formed to identify possible alterations in MMP activity
due to IGF-1 stimulation. Following 24-hour treatment of
DU145 cells with IGF-1, MMP-9 and MMP-2 activity was
increased and this enhanced activity was inhibited or
abolished in the presence of wortmannin or PD98059
(Fig. 2). There was no change in MMP-1 expression after
IGF-1 treatment (Fig. 2), indicating that the activity of this
protein does not appear to be regulated by IGF-1, and that
the effects of IGF-1 are specific for certain MMPs. Intracel-
lular and secreted protein levels were examined using
immunoblot analysis of cell lysates and conditioned
media, respectively. IGF-1 initially induced an increase in
MMP-9 intracellular protein expression with time (8 hrs
and 24 hrs), followed by a decrease at longer time points
(Fig. 3A). Extracellular protein expression of MMP-9 was
observed at 32 hrs and 48 hrs of IGF-1-treatment (Fig. 3B),
indicating secretion of MMP-9 due to stimulation with
IGF-1. The increase in cellular expression of MMP-9 with
8-hour IGF-1 treatment was found to be attenuated in the
presence of either of the inhibitors wortmannin or
PD98059 (Fig. 3C). On the other hand, MMP-2 intracel-
lular protein expression did not change with IGF-1 treat-
ment over the course of 48 hours (results not shown),
irrespective of the presence of wortmannin and PD98059
(Fig. 3C). Similarly, secreted levels of MMP-2 also showed
no change with 24-hour IGF-1 treatment (Fig. 3D).
IGF-1 regulation of TIMP-2 secreted protein levels via the 
PI3-K and MAPK pathways
Since we did not observe any alterations in protein expres-
sion of MMP-2, it is likely that IGF-1 regulates MMP-2
activity by mechanisms other than an increase in its cellu-
lar expression. TIMP-1 and TIMP-2 are inhibitors of
MMPs and have been shown to be involved in their regu-
lation. Specifically, TIMP-1 has a negative regulatory effect
on MMP-9 and TIMP-2 is known to have a dual stimula-
tory and inhibitory effect on the activity of on MMP-2
[25]. Therefore, we looked for alterations in the secreted
protein levels of TIMP-1 and TIMP-2 upon IGF-1 treat-
ment. Secreted TIMP-2 levels were found to be increased
in the presence of IGF-1 and decreased in the presence of
IGF-1 and wortmannin or PD98059 (Fig. 4A). Therefore,
TIMP-2 levels are regulated by IGF-1 via the PI3-K and
MAPK pathways, paralleling the regulation of the activity
of MMP-2 by IGF-1 as determined by gelatin zymography
(Fig. 2). On the other hand, secreted TIMP-1 levels remain
unchanged in the presence of IGF-1 (Fig. 4B).
Discussion
Studies described herein have addressed whether IGF-1
has a direct effect on the invasive potential of DU145
prostate carcinoma cells and have established some of the
mechanisms involved. This is the first study, to our knowl-
edge, showing that the addition of exogenous IGF-1 to
prostate cancer cells results in a significant increase in
invasive potential, and that these effects are reduced by
inhibiting IGF-1R, the MAPK pathway or the PI3-K path-
way. Previous studies have shown that the inhibition of
IGR-1R reduced invasion in the PC-3 prostate cancer cell
line [10], confirming the requirement for IGF signalling
but not showing that it was sufficient alone to induce
invasion. Thus, surprisingly, a positive effect of IGF-1
alone on invasive capacity in this tumour type had not
been documented until now. The inhibition of IGF-1R
phosphorylation using the MAB391 neutralizing anti-
body is dose-dependent in DU145 cells and the observed
inhibition can be reversed in the presence of excess IGF-1
[23], suggesting that MAB391 inhibits IGF-1R phosphor-
ylation in a manner that is competitive with the IGF-1 lig-
and.Cancer Cell International 2008, 8:10 http://www.cancerci.com/content/8/1/10
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IGF-1 stimulates the in vitro invasion of DU145 cells through the IGF-1R, via both the PI3-K and MAPK pathways Figure 1
IGF-1 stimulates the in vitro invasion of DU145 cells through the IGF-1R, via both the PI3-K and MAPK path-
ways. A) Representative experiment showing number of cells invading a Matrigel-coated membrane relative to surface area. 
Serum-deprived DU145 cells were treated for 24 hours with indicated concentrations of IGF-1 after which 5 × 104 cells were 
allowed to invade through the Matrigel for 24 hours. IGF-1 treatment induces a dose-responsive increase in the invasive poten-
tial of DU145 cells through Matrigel compared to invasion in mock-treated cells that were administered a volume of 1× PBS 
similar to the 200 ng/ml condition. (*p < 0.05; Fisher exact T-test). B) Number of cells invading a Matrigel-coated membrane rel-
ative to surface area. Serum-deprived DU145 cells were pretreated for 24 hours with a neutralizing IGF-1R antibody (IGF-
1Rab), then treated with 200 ng/ml IGF-1 for 24 hours. 5 × 104 cells were allowed to invade through the Matrigel for 24 hours. 
The increase in Matrigel invasion of DU145 cells stimulated by IGF-1 is significantly decreased in the presence of the IGF-1R 
neutralizing antibody (*p < 0.05; Fisher exact T-test) The control consisted of adding a similar amount of the vehicle (1× PBS) for 
each addition in the test conditions. C,D,E,F) Serum-deprived DU145 cells were pre-treated in the presence or absence of 
the PI3-K inhibitor wortmannin or the MEK inhibitor PD98059 for 1 hour, then treated with 200 ng/ml IGF-1 for 1 hour, main-
taining previous inhibitor conditions. The control consisted of adding a similar amount of the vehicle (1× PBS for IGF-1, DMSO 
for wortmannin or PD98059) for each addition in the test conditions. C) Immunoblotting shows an increase in Akt phosphor-
ylation in DU145 cells treated with IGF-1, but not in the presence of wortmannin. D) Immunoblotting shows an increase in the 
phosphorylation of p42/44 MAPK in DU145 cells treated with IGF-1, but not in the presence of PD98059. E,F) Representative 
experiments showing number of cells invading a Matrigel-coated membrane relative to surface area. At the end of the respec-
tive treatments, 5 × 104 cells were added to each invasion chamber and allowed to invade through the Matrigel for 24 hours. 
E) Each condition was performed on three separate occasions. The relative rate of inhibition by wortmannin of the IGF-1 
effect on invasion was consistent across experiments, with a mean of 0.79 +/- 0.083. F) Each condition was performed on four 
separate occasions. The relative rate of inhibition by PD98059 of the IGF-1 effect on invasion was consistent across experi-
ments, with a mean of 0.37 +/- 0.096.
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The data indicates a regulatory role of IGF-1 signalling via
both the PI3-K and MAPK pathways in DU145 prostate
carcinoma cells. Phosphorylation of key elements of these
pathways, Akt and MAPK, following IGF-1 treatment con-
firmed the role of the PI3-K and MAPK pathways in IGF-1
signalling and correlates with invasive capacity. P-Akt lev-
els were found to be decreased in the presence of wort-
mannin as expected; however they also increased in the
presence of PD98059, possibly due to increased IGF-1 sig-
nalling through the PI3-K pathway when the MAPK path-
way is blocked. Contrary to the results described here,
Pfeil and colleagues [26] showed that MEK inhibition did
not affect P-Akt activation in DU145 cells. This difference
using the same cell line could be due the use of a lower
drug concentration of 20 μM, perhaps insufficient to effec-
tively block the MAPK pathway, whereas our cells were
treated with 50 μM PD98059. Our results also show that
IGF-1-induced P-MAPK levels were decreased by
PD98059 as expected, and unaffected by wortmannin.
Together, these results indicate that IGF-1/IGF-1R signal-
IGF-1 induces the activity of MMP-9 and MMP-2 via both PI3-K and MAPK pathways Figure 2
IGF-1 induces the activity of MMP-9 and MMP-2 via both PI3-K and MAPK pathways. Serum-deprived DU145 cells 
were pre-treated for 1 hour with either the PI3-K inhibitor wortmannin or the MEK inhibitor PD98059, then treated with IGF-
1 for 24 hours in the same conditions of inhibitor use. The control consisted of adding a similar amount of the vehicle (1× PBS 
for IGF-1, DMSO for wortmannin or PD98059) for each addition in the test conditions. Conditioned media was concentrated, 
normalized to cell number and used for gelatin zymography. Protease activity is seen as clear digested bands at 92 kDa for 
MMP-9, at 72 kDa for MMP-2 and at 52 kDa for MMP-1 (A). Densitometric quantification indicates that MMP-9 activity is 
increased by IGF-1, with this increase prevented by either wortmannin or PD98059 (B). MMP-2 activity is also induced by IGF-
1; presence of either inhibitor completely abrogates this activation (C). The activity of MMP-1 is unaffected by IGF-1 both in 
the absence and presence of wortmannin or PD98059 (D).
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ling via the PI3-K and MAPK pathways leads to enhanced
invasive capacity in DU145 cells, and that inhibition of
either pathway impairs invasion.
We examined the effects of IGF-1 on the collagenolytic
activity of DU145 cells using gelatin zymography which is
an extremely sensitive technique that can detect picogram
levels of MMPs. There is precedence for the role of IGF-1
in this regard via its effects on MMPs, such as MMP-2 and
MMP-9 in MCF-7 breast cancer cells and in androgen-
independent PC3 prostate cancer cells [27,10]. IGF-1 was
shown to increase the activity of MMP-2 and MMP-9;
however MMP-1 levels remained unchanged, indicating
specificity of action of IGF-1. Both MMP-2 and MMP-9
activity levels were decreased in the presence of either
wortmannin or PD98059, indicating that the regulatory
role of IGF-1 on enzyme activity is transmitted via the PI3-
K and MAPK pathways. Inhibition of either signalling
pathway resulted in complete inhibition of MMP-2 activ-
ity, suggesting the requirement of activation of both path-
ways in MMP-2 regulation. On the other hand, MMP-9
activity was decreased to baseline levels in the presence of
either wortmannin or PD98059. The increase in activity of
MMP-9 induced by IGF-1 was found to correlate with an
increase in protein expression and secretion from the cell,
whereas this was not the case for MMP-2 (Fig. 3).
It is the balance between MMPs and their inhibitors
(TIMPs) that determines the proteolytic degradation of
the matrix and if this balance is disrupted, prostate
IGF-1 regulates the activity of MMP-9 and MMP-2 by different mechanisms Figure 3
IGF-1 regulates the activity of MMP-9 and MMP-2 by different mechanisms. A, B) DU145 cells were treated with 
IGF-1 for varying amounts of time and both cell lysate and conditioned media were collected. A) Immunoblot of cell lysates 
indicates that IGF-1 induces an increase in the cellular protein expression of MMP-9 in a time-dependent manner at 8 and 24 
hours of treatment, then a decrease at 32 and 48 hours of treatment. B) Immunoblot of conditioned media indicates that IGF-
1 induces an increase in the secreted protein expression of MMP-9 in a time-dependent manner seen after 32 hours of treat-
ment. The amount of protein in each lane is normalized to cell number. C, D)DU145 cells were pre-treated with the PI3-K 
inhibitor wortmannin or the MEK inhibitor PD98059, then treated with IGF-1 for 8 hours and both cell lysate and conditioned 
media were collected. The control consisted of adding a similar amount of the vehicle (1× PBS for IGF-1, DMSO for wortman-
nin or PD98059) for each addition in the test conditions. C) Immunoblot of lysates indicates that the IGF-1-induced increase in 
the cellular protein expression of MMP-9 is attenuated in the presence of PD98059 and even more so in the presence of wort-
mannin. No change in MMP-2 expression is seen in any of the conditions. D) Protein expression of MMP-2 in conditioned 
media is unaltered compared to mock-treated control cells, whereas that of MMP-9 follows the same pattern seen in cell 
lysates. The amount of protein in each lane is normalized to cell number. All blots are representative of three separate experi-
ments in which a similar trend was observed.
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tumour growth and progression are significantly affected
[28]. We analyzed the response of both TIMP-1 and TIMP-
2 to IGF-1 and found that TIMP-1 levels are unaltered,
suggesting that TIMP-1 expression is not regulated by this
growth factor. On the other hand, secreted TIMP-2 levels
increased with IGF-1 and decreased in the presence of
wortmannin and PD98059, paralleling the results seen for
MMP-2 and MMP-9 enzyme activity. Therefore, IGF-1
appears to have a stimulatory effect on TIMP-2 protein
expression, and on MMP-2 and MMP-9 activity. TIMP-2 is
known to bind to proMMP-2 and facilitate enzyme activa-
tion [29]. The correlation between TIMP-2 protein levels
and MMP-2 activity indicates that TIMP-2 induction may
be a possible mechanism of stimulation of MMP-2 activ-
ity by IGF-1. To verify this however, further experiments
would be needed, such as the analysis of IGF-1-stimulated
MMP-2 activity in DU145 cells in the presence of TIMP-2
inhibition.
Conclusion
The results from this study show that IGF-1 is a key regu-
lator of the invasive potential of DU145 prostate cancer
cells. This effect of IGF-1 appears to be mediated at least
in part through its ability to regulate MMP-2 and MMP-9
activity and secreted TIMP-2 protein levels, effects which
are transduced via the PI3-K and MAPK pathways. Further
work is necessary to elucidate additional elements of the
complete mechanism for IGF-1 induction of prostate can-
cer invasion.
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